Related references
Note: Only part of the references are listed.The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
Anna Malczewska et al.
ADVANCES IN MEDICAL SCIENCES (2020)
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
K. Oberg et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
Janice M. Mehnert et al.
CANCER (2020)
c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs
Maya Elena Lee et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2020)
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature
S. M. Sadowski et al.
ENDOCRINE-RELATED CANCER (2020)
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances
Julie M. Guilmette et al.
ADVANCES IN ANATOMIC PATHOLOGY (2019)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases
Anja Frederiksen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours
Aldo Scarpa
ANNALES D ENDOCRINOLOGIE (2019)
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors
Paloma Cejas et al.
NATURE MEDICINE (2019)
Applications of liquid biopsies for cancer
Austin K. Mattox et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors
Amit Tirosh et al.
CANCER (2019)
The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors
Bhavina D. O. Batukbhai et al.
PANCREAS (2019)
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
Tobias Hofving et al.
ENDOCRINE-RELATED CANCER (2018)
Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas
Vaishali I. Parekh et al.
ENDOCRINE-RELATED CANCER (2018)
DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment
E. B. Conemans et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors
Amit Tirosh et al.
FUTURE ONCOLOGY (2018)
Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium
Andrea Mafficini et al.
JOURNAL OF ENDOCRINOLOGY (2018)
NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines
Manisha H. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors
Mariano J. Alvarez et al.
NATURE GENETICS (2018)
A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors
Anna Malczewska et al.
NEUROENDOCRINOLOGY (2018)
Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors
Cansu G. Genc et al.
JOURNAL OF SURGICAL ONCOLOGY (2018)
Characterization of the Neuroendocrine Tumor Immune Microenvironment
Annacarolina da Silva et al.
PANCREAS (2018)
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Joo Young Kim et al.
CLINICAL CANCER RESEARCH (2017)
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Aatur D. Singhi et al.
CLINICAL CANCER RESEARCH (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors
Diana Martins et al.
TARGETED ONCOLOGY (2017)
Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas
Huan Wang et al.
NATURE COMMUNICATIONS (2017)
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Joo Kyung Park et al.
ONCOTARGET (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).
E. Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors
L. Antonuzzo et al.
CANCER TREATMENT REVIEWS (2017)
Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?
Yehonatan Bar-Moshe et al.
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY (2017)
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2016)
Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
Faidon-Marios Laskaratos et al.
BRITISH JOURNAL OF CANCER (2016)
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
J. Cros et al.
ENDOCRINE-RELATED CANCER (2016)
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
Samira M. Sadowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors
Xavier M. Keutgen et al.
SURGERY (2016)
Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy
Jennifer A. Chan et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place
Louis de Mestier et al.
ANNALS OF SURGERY (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Timothy J. Hobday et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
Yoon Suk Lee et al.
MEDICINE (2015)
Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas
M. Kyle Cromer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management
Jordan M. Cloyd et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Anguraj Sadanandam et al.
CANCER DISCOVERY (2015)
Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine Tumors
Ilaria Marinoni et al.
GASTROENTEROLOGY (2014)
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)
Rajesh V. Thakker
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dual Inhibition of PI3K and mTOR Signaling Pathways Decreases Human Pancreatic Neuroendocrine Tumor Metastatic Progression
Clarisse Djukom et al.
PANCREAS (2014)
Genomic landscape of pancreatic neuroendocrine tumors
Niklas Gebauer et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
Ilaria Passacantilli et al.
ONCOTARGET (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Current Understanding of the Molecular Biology of Pancreatic Neuroendocrine Tumors
Jianliang Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1
Yanan Cao et al.
NATURE COMMUNICATIONS (2013)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries
V. Corbo et al.
ANNALS OF ONCOLOGY (2012)
Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors An Analysis of the AJCC and ENETS Staging Classifications
Jonathan R. Strosberg et al.
ANNALS OF SURGERY (2012)
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
Daniela Speisky et al.
CLINICAL CANCER RESEARCH (2012)
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Rajesh V. Thakker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
Roeland F. de Wilde et al.
MODERN PATHOLOGY (2012)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes
Christopher M. Heaphy et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
Staffan Welin et al.
CANCER (2011)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus
James C. Yao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression
Francesco Panzuto et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Irvin M. Modlin et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann et al.
CANCER LETTERS (2010)
Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions
Aaron D. Goldberg et al.
CELL (2010)
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases
Vincenzo Corbo et al.
ENDOCRINE-RELATED CANCER (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients
Jan Franko et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2010)
Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres
Peter W. Lewis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Most mammalian mRNAs are conserved targets of microRNAs
Robin C. Friedman et al.
GENOME RESEARCH (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)
Joseph A. Blansfield et al.
SURGERY (2007)
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors
Jun Zhang et al.
CANCER (2007)
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I. Duran et al.
BRITISH JOURNAL OF CANCER (2006)
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior
Claudia Roldo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
A Couvelard et al.
BRITISH JOURNAL OF CANCER (2005)
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors
AM Marion-Audibert et al.
GASTROENTEROLOGY (2003)
Regulation of angiogenesis by hypoxia: role of the HIF system
CW Pugh et al.
NATURE MEDICINE (2003)
Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors -: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis
M Papotti et al.
VIRCHOWS ARCHIV (2002)
Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease
SK Libutti et al.
SURGERY (2000)
Pancreatic involvement in von Hippel-Lindau disease
PR Hammel et al.
GASTROENTEROLOGY (2000)
Share Paper
